USA flag logo/image

An Official Website of the United States Government

TOPIC 229: PHASE I AMPK DEV. OF MOLECULAR PHARMACODYNAMIC ASSAYS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
94171
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
N43CM0800052
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOASSAY SYSTEMS, LLC
3423 INVESTMENT BLVD, STE 11 HAYWARD, CA 94545-
View profile »
Woman-Owned: No
Minority-Owned: Yes
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: TOPIC 229: PHASE I AMPK DEV. OF MOLECULAR PHARMACODYNAMIC ASSAYS
Agency: HHS
Contract: N43CM0800052
Award Amount: $149,995.00
 

Abstract:

AMP-activated protein kinase (AMPK) is a serine/threonine kinase that is a member of a metabolite sensing protein kinase family. AMPK is involved in controlling cellular metabolism and cell proliferation and when activated has been found to be a potent tum or suppressor. Despite a lot of progress in the discovery of therapeutic agents, a pharmacodynamic assay for AMPK is missing. In this proposed research, BioAssay Systems aims to develop a rapid, sensitive, robust and rigorous assay for AMPK activity in tis sue extract. In the Phase I period, BioAssay Systems will select a suitable pan antibody and coat it onto 96-well plates. The immobilized antibody will capture all AMPK protein and isolate it from any potentially interfering enzymes such as other kinases a nd phosphatases. The captured AMPK remains active so that its activity will be directly measured using a fluorescence technology. At the end of the Phase I period, BioAssay Systems will have established experimental conditions and characterized assay perfo rmance including detection limit, reagent stability, reproducibility, variation and accuracy. The SOP of the research pharmacodynamic assay for AMPK will be delivered to NCI. In the Phase II period, BioAssay Systems will further validate the assay in vario us normal and multiple tumor tissues. Studies will be performed to correlate results in tumor versus surrogate tissues such as blood, serum or plasma. Correlation studies will also be compared in human versus laboratory animals (e.g., mouse and rat). This proposal presents a generic platform technology, the successful development and application of which will allow BioAssay Systems to rapidly develop pharmacodynamic assays for other important cancer targets such as kinases, phosphatases and proteases of int erest to NCI.

Principal Investigator:

Frank Huang

Business Contact:

Small Business Information at Submission:

BIOASSAY SYSTEMS, LLC
BIOASSAY SYSTEMS, LLC 3423 INVESTMENT BLVD, STE 11 HAYWARD, CA 94545

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No